Soleno Therapeutics (SLNO) Total Non-Current Liabilities (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Total Non-Current Liabilities data on file, last reported at $111.2 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $111.2 million, up 63.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $111.2 million (up 63.3% YoY), and the FY2025 annual result was $113.2 million, up 59.27% from the prior year.
• Total Non-Current Liabilities declined to $111.2 million in Q1 2026 per SLNO's latest filing, from $113.2 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $113.2 million in Q4 2025 and troughed at $7.2 million in Q2 2022.
• A 5-year average of $39.4 million and a median of $13.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities plunged 41.25% in 2024, then soared 838.95% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $7.3 million in 2022, then jumped by 59.08% to $11.6 million in 2023, then surged by 510.81% to $71.1 million in 2024, then soared by 59.27% to $113.2 million in 2025, then slipped by 1.79% to $111.2 million in 2026.
• Business Quant data shows SLNO's Total Non-Current Liabilities at $111.2 million in Q1 2026, $113.2 million in Q4 2025, and $85.6 million in Q3 2025.